Xuefeng Wang
Associate Member/Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (29)
Cancer transcriptomic data are widely leveraged to evaluate the prognostic relevance of targeted genes. However, most basic and translational studies continue to rely on univariable survival analysis, which often fails to capture the full prognostic potential of genes or account for their biological context. Recognizing the complexity of revealing multifaceted prognostic effects, especially when incorporating covariates and variable thresholds, we present the Cancer Gene Prognosis Atlas (CGPA), an interactive tool specifically designed for basic and molecular cancer researchers. CGPA provides an intuitive, user-friendly interface that enables in-depth, customizable prognostic analysis across cancer types. Beyond single-gene analyses, it supports data-driven exploration of gene pairs and gene–hallmark relationships, providing insights into key mechanisms such as synthetic lethality and immunosuppression. CGPA further extends its capabilities to assess multigene panels using both public and user-provided data and includes a dedicated portal for cancer immunotherapy datasets. Collectively, CGPA’s comprehensive yet user-friendly toolkit enables researchers to interrogate the prognostic landscape of genes with precision, tailor analyses to specific biological hypotheses, and accelerate biomarker discovery and validation through the integration of both mechanisticically-informed and data-driven approaches. Implications: CGPA is a streamlined, interactive platform for multicontext gene-centric prognostic analysis, simplifying biomarker discovery and validation for molecular and basic cancer scientists and bridging a critical gap in translational cancer research.
Year:
2026
Prolonged or indefinite systemic therapy remains standard for advanced clear cell renal cell carcinoma (ccRCC), often resulting in cumulative toxicities and treatment burden. We conducted a single-arm phase 2 trial of a fixed-duration regimen of pembrolizumab plus high-dose interleukin-2 in treatment-naive advanced ccRCC. Among 26 patients treated, after a median follow-up of 76.4 months, the objective response rate was 73%, with complete responses in 42%. Median overall survival was not reached, with 5-year survival of 73%; median progression-free survival was 19.3 months; and median treatment-free survival was 23.8 months, with 42% of patients remaining treatment-free at 5 years. No grade 5 adverse events occurred, and no patient with durable disease control experienced persistent grade ≥2 toxicities. Correlative analyses identified immune patterns associated with durable benefit, including enrichment of CD16⁺ natural killer cells, suppression of PD-1⁺ T-cell frequencies, and coordinated chemokine, complement, and PKC/TGF-β pathway activation. ClinicalTrials.gov identifier: NCT02964078.
Year:
2025
Directed acyclic graph for Cox proportional hazards regression. Directed acyclic graph representing all variables considered in building multivariable models for the Cox proportional hazards regression representing the associations of muscle changes with PDAC outcomes.
Year:
2025
Directed acyclic graph for generalized linear model. Directed acyclic graph representing all variables considered in building multivariable models for the generalized linear models representing the associations of PDAC diagnosis with post-diagnosis muscle changes.
Year:
2025
Background: Muscle loss influences pancreatic ductal adenocarcinoma (PDAC) outcomes, but treatment-related edema may cause overestimation of total skeletal muscle area (tSMA), confounding our understanding of muscle changes. However, no studies have quantified the impact of edema on tSMA and psoas skeletal muscle area (pSMA) changes. Thus, we sought to (i) assess the impact of edema on tSMA and pSMA changes between diagnosis and follow-up and (ii) explore the utility of pSMA as a clinically relevant measure of muscle and muscle loss among patients with PDAC. Methods: Body composition was measured using CT scans at diagnosis and follow-up from 95 patients enrolled in the Florida Pancreas Collaborative cohort study. Edema was assessed by opacifications in subcutaneous fat, and tSMA and pSMA changes were expressed as percent change between diagnosis and follow-up. We used multivariable generalized linear models to estimate mean tSMA and pSMA changes overall and by edema status. Spearman correlation was used to measure interrelationships of tSMA and pSMA. Results: tSMA increased between diagnosis and follow-up (Δ = 0.66) but only in patients with edema (Δ = 3.35) whereas non-edematous patients lost tSMA (Δ = −2.03). Conversely, pSMA decreased regardless of edema status. Furthermore, tSMA and pSMA were strongly correlated overall ( r = 0.75) and in non-edematous patients ( r = 0.83). Conclusions: Edema inflated estimates of tSMA at follow-up in patients with PDAC, but pSMA was impervious to edema and may represent a suitable proxy for tSMA. Impact: pSMA is a reliable measure of muscle and muscle loss and should be considered in future studies assessing muscle loss in patients with PDAC.
Year:
2025
Patient-derived organoids (PDOs) are emerging as advanced 3D ex vivo novel alternative method (NAM) preclinical models, offering significant advantages over traditional cell lines and monolayer cultures for therapeutic development. In this study, we established PDOs from surgically resected fresh tissues of human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) across anatomical sites, tumor T-categories, and sample types. These PDOs faithfully recapitulate the tumor’s pathology, mutational profile, and drug response. To enable rapid classification of PDO identity, we developed a new convolutional neural network (CNN) model, TransferNet-PDO, which accurately distinguished tumor versus normal PDOs in culture using digital histopathology images (AUC≥0.88). PDOs maintained stable cultures and were cryopreserved between passages 5 and 12. Immunohistochemistry (IHC) staining (PanCK, p63, Cytokeratin 13, Ki67) confirmed squamous phenotype and histologic aggression of the original tumor. For tumors harboring TP53 mutations by whole-exome sequencing (WES), PDOs retained the corresponding p53 functional status as confirmed by IHC (enhanced or loss of expression). Somatic mutational landscape revealed that PDOs preserved driver somatic mutations, copy number variations (CNVs), and clonal architecture including low-prevalence subclones. Drug sensitivity assessment of PDOs showed that cisplatin reduced cell viability, whereas cetuximab and lenvatinib had minimal effects. Chemoradiation led to greater tumor organoid killing compared to radiation or chemotherapy alone. This study presents an integrated HNSCC PDO platform combining tissue biobanking, organoid establishment, multi-omics characterization, functional drug screening, and AI-driven histopathologic classification, providing a comprehensive and scalable system for translational cancer research.
Year:
2025
Motivation Spatial transcriptomic (ST) technologies, such as GeoMx Digital Spatial Profiler, are increasingly utilized to investigate the role of diverse tumor microenvironment components, particularly in relation to cancer progression, treatment response, and therapeutic resistance. However, in many ST studies, the spatial information obtained from immunofluorescence imaging is primarily used for identifying regions of interest (ROIs) rather than as an integral part of downstream transcriptomic data analysis and interpretation. Results We developed ROICellTrack, a deep learning-based framework that better integrates cellular imaging with spatial transcriptomic profiling. By analyzing 56 ROIs from urothelial carcinoma of the bladder and upper tract urothelial carcinoma, ROICellTrack identified distinct cancer–immune cell mixtures, characterized by specific transcriptomic and morphological signatures and receptor–ligand interactions linked to tumor content and immune infiltrations. Our findings demonstrate the value of integrating imaging with transcriptomics to analyze spatial omics data, improving our understanding of tumor heterogeneity and its relevance to personalized and targeted therapies. Availability and implementation ROICellTrack is publicly available at https://github.com/wanglab1/ROICellTrack.
Year:
2025
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we examined patients’ intratumoral immune infiltrates and observed that elevated levels of immunoregulatory macrophages in pre-infusion tumor biopsies are correlated with poor clinical responses. CAR T cell-produced interferon-gamma (IFN-γ) promotes the expression of inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Mechanistically, iNOS-expressing macrophages upregulated the p53 pathway, mediating apoptosis and cell cycle arrest in CAR T cells, while downregulating the MYC pathway involved in ribosome biogenesis and protein synthesis. Furthermore, CAR T cell metabolism is compromised by depletion of glycolytic intermediates and rewiring of the TCA cycle. Pharmacological inhibition of iNOS enhances the CAR T cell treatment efficacy in B cell tumor-bearing mice. Notably, elevated levels of iNOS+CD14+ monocytes were observed in leukaphereses of patients with non-durable response to CAR T cell therapy. These findings suggest that mitigating iNOS in tumor-associated macrophages (TAMs) by blocking IFN-γ secretion from CAR T cells will improve outcomes for LBCL patients.
Year:
2025
Purpose: Immune checkpoint blockade holds promise for treating bacillus Calmette-Guerin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC). In this phase II study, we investigated the safety and efficacy of durvalumab, a human IgG1 monoclonal antibody, against BCG-unresponsive carcinoma in situ (CIS). Patients and Methods: Patients with BCG-unresponsive CIS-containing NMIBC received durvalumab IV at 1,500 mg every 4 weeks for up to 12 months. The primary endpoint was complete response (CR) rate at month 6, defined by negative cystoscopy, urine cytology, and absence of high-grade recurrence on bladder mapping biopsy. The null hypothesis specified a CR rate of 18% and alternative hypothesis of 40%. According to the Simon two-stage design, if ≤3/13 patients achieved CR during stage 1, the trial is stopped due to futility. Results: Between March 8, 2017, and January 24, 2020, 17 patients were accrued whereas 4 withdrew from study treatment after bladder biopsy at month 3 was positive for CIS. Two of 17 (12%) achieved a CR at month 6, with duration of response of 10 and 18 months, respectively. A single grade 3 lipase elevation was attributed to durvalumab, and immune-related adverse events were observed in 7/17 (41%) patients. Only 1/17 patients had high programmed death-ligand 1 expression pretreatment. On RNA sequencing, complement activation genes were elevated posttreatment, along with enrichment of tumor-associated macrophage signature. Conclusions: Durvalumab monotherapy conferred minimal efficacy in treating BCG-unresponsive CIS of the bladder, with 6-month CR of 12%. Complement activation is a potential mechanism behind treatment resistance.
Year:
2025
Supplementary Table S1. Patient cohort: Clinical data and assays Supplementary Table S2. Sample cohort: Clinical data and assays Supplementary Table S3. Pre-ICB bulk RNA-seq cohort, 63 samples Supplementary Table S4. Pre-Post ICB matched bulk RNA-seq, 28 samples, 14 patient pairs Supplementary Table S5. Number of reads for each bulk RNA-seq sample (85 samples) Supplementary Table S6. Tissue single-cell RNA-seq quality control and sample metadata (54 samples) Supplementary Table S7. Blood single-cell RNA-seq quality control and sample metadata (55 samples) Supplementary Table S8. Multiplex immunofluorescence sample cohort (44 samples) Supplementary Table S9. GeoMx sample cohort (15 samples) Supplementary Table S10. CosMx sample cohort (13 samples) Supplementary Table S11: Genes differentially expressed between MCC that respond to anti-PD-1/PD-L1 therapy (n=31) and MCC that do not respond to anti-PD-1/PD-L1 therapy (n=32) in the pre-ICB cohort (n=63). Supplementary Table S12. Enrichr results of differentially expressed genes (FDR
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (56)
youngchul kim
Moffitt Cancer Center
Jose G. Trevino
Virginia Commonwealth University
Sylvia Crowder
Assistant Member
H Lee Moffitt Cancer Center and Research Institute
Yun Pyo Kang
Assistant Professor
Seoul National University
Tiago Biachi de Castria
Associate Professor
University of South Florida
Brian Pierce
University of Maryland
Ghulam Rasool
Assistant Member
Moffitt Cancer Center
Johannes Fahrmann
Assistant Professor
The University of Texas MD Anderson Cancer Center
Vernon Sondak
Chair
H Lee Moffitt Cancer Center and Research Institute
Vic VELANOVICH
University of South Florida
Jeffrey B. Cheng
Assistant Professor
University of California
Nikhil Khushalani
Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology
H Lee Moffitt Cancer Center and Research Institute
Sarah Judge
Research Assistant Professor
University of Florida
Marco Davila
SVP, Translational Research
Roswell Park Comprehensive Cancer Center
Jianmin Wang
Associate Professor
Roswell Park Comprehensive Cancer Center
Xinlei Mi
Assistant Professor
Northwestern University Feinberg School of Medicine
Adrian V. Lee
University of Pittsburgh
Julio Chavez
Associate Professor
Moffitt Cancer Center
Christina Bachmeier
H Lee Moffitt Cancer Center and Research Institute
Hiroshi Kotani
Professor and Cairman
University of the Ryukyus
Raymond Jaihyun Cho
Professor
UCSF Medical Center
Qianxing Mo
Senior Member
H Lee Moffitt Cancer Center and Research Institute
Anders Berglund
H Lee Moffitt Cancer Center and Research Institute
Ioannis Zervantonakis
Associate Professor
University of Pittsburgh
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
Amod Sarnaik
Senior Member / Full Professor
H Lee Moffitt Cancer Center and Research Institute
Marion Subklewe
Head of Hematology with Focus on Cellular Therapy, CAR T and ECTU & LMU - Gene Center - Head of the Laboratory of Translational Cancer Immunology
Ludwig-Maximilians-Universität München
Muhammad Junaid Tariq
Clinical Assisstant Professor
University of Florida
Alexander Anderson
Department Chair
H Lee Moffitt Cancer Center and Research Institute
Jaehyuk Choi
Associate Professor
Yale University School of Medicine
Roger Li
H Lee Moffitt Cancer Center and Research Institute
Jose Conejo-Garcia
Duke Science and Technology Scholar
Duke Medicine
Julio Pow-Sang
Chair
H Lee Moffitt Cancer Center and Research Institute
Timothy Shaw
Assistant Member/Professor
Moffitt Cancer Center
Pei-Fen Kuan
Professor
Stony Brook University
Brooke Fridley
Director
Children's Mercy Hospital
Michael Jain
Associate Member
H Lee Moffitt Cancer Center and Research Institute
Jonathan S. Zager
H Lee Moffitt Cancer Center and Research Institute
Neeraj Y Saini
Associate Professor
The University of Texas MD Anderson Cancer Center
Michael Schell
Senio Member
H Lee Moffitt Cancer Center and Research Institute
Marion Subklewe
LMU University Hospital
Kun Jiang
-
Andrew Judge
Professor
University of Florida
Paulo Rodriguez
Senior Member-Professor
H Lee Moffitt Cancer Center and Research Institute
Xiaoqing Yu
Associate Professor
H Lee Moffitt Cancer Center and Research Institute
Andrew Brohl
Associate Member
H Lee Moffitt Cancer Center and Research Institute
Jose Pimiento
H Lee Moffitt Cancer Center and Research Institute
Gustavo Borjas
Case Western Reserve University
Spencer Ng
Assistant Professor
Washington University in St. Louis
Dung-Tsa Chen
H Lee Moffitt Cancer Center and Research Institute
Kenneth Tsai
Vice Chair of Research, Senior Member
H Lee Moffitt Cancer Center and Research Institute
Paul Stewart
Research Associate Professor
University of Utah
Christopher J. Whelan
H Lee Moffitt Cancer Center and Research Institute
Sergei Koralov
Associate Prof
NYU School of Medicine
Christopher Cubitt
Core Staff Scientist
H Lee Moffitt Cancer Center and Research Institute
Aleksandra Karolak
Assistant Professor - Secondary Appointment
Moffitt Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.